CN103736017A - 一种治疗肋间神经痛的中药组合物及其制备方法 - Google Patents
一种治疗肋间神经痛的中药组合物及其制备方法 Download PDFInfo
- Publication number
- CN103736017A CN103736017A CN201310751102.2A CN201310751102A CN103736017A CN 103736017 A CN103736017 A CN 103736017A CN 201310751102 A CN201310751102 A CN 201310751102A CN 103736017 A CN103736017 A CN 103736017A
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- rhizoma
- chinese medicine
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 123
- 206010049949 Intercostal neuralgia Diseases 0.000 title claims abstract description 67
- 238000002360 preparation method Methods 0.000 title claims abstract description 42
- 239000000203 mixture Substances 0.000 title claims abstract description 34
- 229940079593 drug Drugs 0.000 claims abstract description 36
- 230000002829 reductive effect Effects 0.000 claims abstract description 15
- 241000218176 Corydalis Species 0.000 claims abstract description 14
- 241000903946 Clematidis Species 0.000 claims abstract description 12
- 235000014375 Curcuma Nutrition 0.000 claims abstract description 7
- 241000132446 Inula Species 0.000 claims abstract description 7
- 238000011282 treatment Methods 0.000 claims description 40
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 33
- 241000628997 Flos Species 0.000 claims description 32
- 238000010438 heat treatment Methods 0.000 claims description 26
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 23
- 210000000582 semen Anatomy 0.000 claims description 21
- 239000007788 liquid Substances 0.000 claims description 20
- 238000000605 extraction Methods 0.000 claims description 19
- 239000000243 solution Substances 0.000 claims description 19
- 238000000108 ultra-filtration Methods 0.000 claims description 18
- 239000002994 raw material Substances 0.000 claims description 17
- 239000003795 chemical substances by application Substances 0.000 claims description 15
- 239000000843 powder Substances 0.000 claims description 14
- 241000237636 Pheretima Species 0.000 claims description 13
- 239000007924 injection Substances 0.000 claims description 13
- 238000002347 injection Methods 0.000 claims description 13
- 241001489978 Eupolyphaga Species 0.000 claims description 12
- 241000545442 Radix Species 0.000 claims description 12
- 239000002775 capsule Substances 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 12
- 239000006187 pill Substances 0.000 claims description 12
- 239000002552 dosage form Substances 0.000 claims description 11
- 239000002674 ointment Substances 0.000 claims description 10
- 230000008901 benefit Effects 0.000 claims description 9
- 238000004821 distillation Methods 0.000 claims description 9
- 238000002481 ethanol extraction Methods 0.000 claims description 9
- 239000000706 filtrate Substances 0.000 claims description 9
- 238000001914 filtration Methods 0.000 claims description 9
- 238000001035 drying Methods 0.000 claims description 8
- 239000006228 supernatant Substances 0.000 claims description 8
- 241000407170 Curcuma Species 0.000 claims description 6
- 241001180876 Saposhnikovia Species 0.000 claims description 6
- 238000010992 reflux Methods 0.000 claims description 6
- 230000006837 decompression Effects 0.000 claims description 5
- 239000008187 granular material Substances 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 5
- 238000004064 recycling Methods 0.000 claims description 5
- -1 electuary Substances 0.000 claims description 4
- JEIPFZHSYJVQDO-UHFFFAOYSA-N ferric oxide Chemical compound O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 claims description 4
- 229940099259 vaseline Drugs 0.000 claims description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 2
- 239000013078 crystal Substances 0.000 claims description 2
- 239000008298 dragée Substances 0.000 claims description 2
- 239000002662 enteric coated tablet Substances 0.000 claims description 2
- 239000007941 film coated tablet Substances 0.000 claims description 2
- 239000007902 hard capsule Substances 0.000 claims description 2
- 239000012567 medical material Substances 0.000 claims description 2
- 238000004321 preservation Methods 0.000 claims description 2
- 239000007901 soft capsule Substances 0.000 claims description 2
- 239000007921 spray Substances 0.000 claims description 2
- 239000007940 sugar coated tablet Substances 0.000 claims description 2
- 230000008719 thickening Effects 0.000 claims description 2
- 239000008280 blood Substances 0.000 abstract description 92
- 210000004369 blood Anatomy 0.000 abstract description 90
- 230000006870 function Effects 0.000 abstract description 15
- 206010061218 Inflammation Diseases 0.000 abstract description 12
- 230000004054 inflammatory process Effects 0.000 abstract description 12
- 208000015181 infectious disease Diseases 0.000 abstract description 8
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 6
- 230000002458 infectious effect Effects 0.000 abstract description 6
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 abstract description 6
- 238000006243 chemical reaction Methods 0.000 abstract description 3
- 210000003712 lysosome Anatomy 0.000 abstract description 3
- 230000001868 lysosomic effect Effects 0.000 abstract description 3
- 239000012528 membrane Substances 0.000 abstract description 3
- 230000035699 permeability Effects 0.000 abstract description 3
- 241000382455 Angelica sinensis Species 0.000 abstract 2
- 241000112528 Ligusticum striatum Species 0.000 abstract 2
- 235000017276 Salvia Nutrition 0.000 abstract 2
- 240000007164 Salvia officinalis Species 0.000 abstract 2
- 244000144730 Amygdalus persica Species 0.000 abstract 1
- 241000045403 Astragalus propinquus Species 0.000 abstract 1
- 241000207199 Citrus Species 0.000 abstract 1
- 244000164480 Curcuma aromatica Species 0.000 abstract 1
- 240000009138 Curcuma zedoaria Species 0.000 abstract 1
- 235000003405 Curcuma zedoaria Nutrition 0.000 abstract 1
- 241001071795 Gentiana Species 0.000 abstract 1
- 241000361919 Metaphire sieboldi Species 0.000 abstract 1
- 244000170916 Paeonia officinalis Species 0.000 abstract 1
- 235000006484 Paeonia officinalis Nutrition 0.000 abstract 1
- 235000006040 Prunus persica var persica Nutrition 0.000 abstract 1
- 235000006533 astragalus Nutrition 0.000 abstract 1
- ZAIPMKNFIOOWCQ-UEKVPHQBSA-N cephalexin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=CC=C1 ZAIPMKNFIOOWCQ-UEKVPHQBSA-N 0.000 abstract 1
- 235000020971 citrus fruits Nutrition 0.000 abstract 1
- 239000001812 curcuma zedoaria berg. rosc. Substances 0.000 abstract 1
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 abstract 1
- 210000004969 inflammatory cell Anatomy 0.000 abstract 1
- 230000028709 inflammatory response Effects 0.000 abstract 1
- 230000002045 lasting effect Effects 0.000 abstract 1
- 210000001539 phagocyte Anatomy 0.000 abstract 1
- 230000000451 tissue damage Effects 0.000 abstract 1
- 231100000827 tissue damage Toxicity 0.000 abstract 1
- 235000019509 white turmeric Nutrition 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 description 100
- 230000036407 pain Effects 0.000 description 100
- 230000000694 effects Effects 0.000 description 38
- 210000004185 liver Anatomy 0.000 description 38
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 32
- 201000010099 disease Diseases 0.000 description 28
- 230000001737 promoting effect Effects 0.000 description 27
- 230000017531 blood circulation Effects 0.000 description 18
- 210000000481 breast Anatomy 0.000 description 18
- 210000001937 intercostal nerve Anatomy 0.000 description 18
- 210000000115 thoracic cavity Anatomy 0.000 description 16
- 201000000736 Amenorrhea Diseases 0.000 description 15
- 206010001928 Amenorrhoea Diseases 0.000 description 15
- 210000001015 abdomen Anatomy 0.000 description 15
- 231100000540 amenorrhea Toxicity 0.000 description 15
- 230000006378 damage Effects 0.000 description 14
- 208000006820 Arthralgia Diseases 0.000 description 13
- 208000014674 injury Diseases 0.000 description 13
- 208000024891 symptom Diseases 0.000 description 13
- 208000019255 Menstrual disease Diseases 0.000 description 12
- 206010011224 Cough Diseases 0.000 description 11
- 208000027418 Wounds and injury Diseases 0.000 description 11
- 229940090044 injection Drugs 0.000 description 11
- 206010000087 Abdominal pain upper Diseases 0.000 description 10
- 241000700199 Cavia porcellus Species 0.000 description 10
- 206010037660 Pyrexia Diseases 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 10
- 210000000232 gallbladder Anatomy 0.000 description 10
- 210000003734 kidney Anatomy 0.000 description 10
- 210000003205 muscle Anatomy 0.000 description 10
- 230000001105 regulatory effect Effects 0.000 description 10
- 210000002784 stomach Anatomy 0.000 description 10
- 206010013935 Dysmenorrhoea Diseases 0.000 description 9
- 239000009636 Huang Qi Substances 0.000 description 9
- 235000009508 confectionery Nutrition 0.000 description 9
- 210000000056 organ Anatomy 0.000 description 9
- 210000003462 vein Anatomy 0.000 description 9
- 208000005171 Dysmenorrhea Diseases 0.000 description 8
- 206010019233 Headaches Diseases 0.000 description 8
- 208000033809 Suppuration Diseases 0.000 description 8
- 210000000988 bone and bone Anatomy 0.000 description 8
- 230000004087 circulation Effects 0.000 description 8
- 231100000869 headache Toxicity 0.000 description 8
- 230000003601 intercostal effect Effects 0.000 description 8
- 210000004072 lung Anatomy 0.000 description 8
- 230000001717 pathogenic effect Effects 0.000 description 8
- 210000000952 spleen Anatomy 0.000 description 8
- 230000008961 swelling Effects 0.000 description 8
- 206010062717 Increased upper airway secretion Diseases 0.000 description 7
- 206010027514 Metrorrhagia Diseases 0.000 description 7
- 208000025865 Ulcer Diseases 0.000 description 7
- 210000003414 extremity Anatomy 0.000 description 7
- 210000002216 heart Anatomy 0.000 description 7
- 208000035861 hematochezia Diseases 0.000 description 7
- 244000052769 pathogen Species 0.000 description 7
- 208000026435 phlegm Diseases 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 231100000397 ulcer Toxicity 0.000 description 7
- 206010010774 Constipation Diseases 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- 208000025747 Rheumatic disease Diseases 0.000 description 6
- 208000019790 abdominal distention Diseases 0.000 description 6
- 230000000202 analgesic effect Effects 0.000 description 6
- 210000001367 artery Anatomy 0.000 description 6
- 230000007812 deficiency Effects 0.000 description 6
- 208000001848 dysentery Diseases 0.000 description 6
- 230000003203 everyday effect Effects 0.000 description 6
- 239000003172 expectorant agent Substances 0.000 description 6
- 230000003419 expectorant effect Effects 0.000 description 6
- 238000005469 granulation Methods 0.000 description 6
- 230000003179 granulation Effects 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 230000003902 lesion Effects 0.000 description 6
- 231100000915 pathological change Toxicity 0.000 description 6
- 230000036285 pathological change Effects 0.000 description 6
- 229940023488 pill Drugs 0.000 description 6
- 230000000552 rheumatic effect Effects 0.000 description 6
- 206010040872 skin infection Diseases 0.000 description 6
- 206010042772 syncope Diseases 0.000 description 6
- 208000011580 syndromic disease Diseases 0.000 description 6
- 210000002435 tendon Anatomy 0.000 description 6
- 206010000077 Abdominal mass Diseases 0.000 description 5
- 206010007247 Carbuncle Diseases 0.000 description 5
- 208000035154 Hyperesthesia Diseases 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 230000009286 beneficial effect Effects 0.000 description 5
- 230000002950 deficient Effects 0.000 description 5
- 238000009826 distribution Methods 0.000 description 5
- 210000002683 foot Anatomy 0.000 description 5
- 210000005036 nerve Anatomy 0.000 description 5
- 208000037920 primary disease Diseases 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 230000008736 traumatic injury Effects 0.000 description 5
- 206010008479 Chest Pain Diseases 0.000 description 4
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 4
- 208000032843 Hemorrhage Diseases 0.000 description 4
- 206010020565 Hyperaemia Diseases 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 206010030113 Oedema Diseases 0.000 description 4
- 208000004880 Polyuria Diseases 0.000 description 4
- 206010040943 Skin Ulcer Diseases 0.000 description 4
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 4
- 206010047700 Vomiting Diseases 0.000 description 4
- 206010052428 Wound Diseases 0.000 description 4
- 238000001467 acupuncture Methods 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 230000035617 depilation Effects 0.000 description 4
- 230000002951 depilatory effect Effects 0.000 description 4
- 230000035619 diuresis Effects 0.000 description 4
- 235000013399 edible fruits Nutrition 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 208000001780 epistaxis Diseases 0.000 description 4
- 208000024756 faint Diseases 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 235000019634 flavors Nutrition 0.000 description 4
- 230000001709 ictal effect Effects 0.000 description 4
- 210000000629 knee joint Anatomy 0.000 description 4
- 230000033001 locomotion Effects 0.000 description 4
- 201000004792 malaria Diseases 0.000 description 4
- 239000002398 materia medica Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000001537 neural effect Effects 0.000 description 4
- 231100000252 nontoxic Toxicity 0.000 description 4
- 230000003000 nontoxic effect Effects 0.000 description 4
- 201000008482 osteoarthritis Diseases 0.000 description 4
- 231100000019 skin ulcer Toxicity 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- 210000001835 viscera Anatomy 0.000 description 4
- 230000008673 vomiting Effects 0.000 description 4
- 208000004998 Abdominal Pain Diseases 0.000 description 3
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 3
- 208000007514 Herpes zoster Diseases 0.000 description 3
- 241000701085 Human alphaherpesvirus 3 Species 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 206010062575 Muscle contracture Diseases 0.000 description 3
- 206010050819 Musculoskeletal chest pain Diseases 0.000 description 3
- 206010035664 Pneumonia Diseases 0.000 description 3
- 208000007536 Thrombosis Diseases 0.000 description 3
- 206010047601 Vitamin B1 deficiency Diseases 0.000 description 3
- 208000031971 Yin Deficiency Diseases 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 208000007474 aortic aneurysm Diseases 0.000 description 3
- 208000006673 asthma Diseases 0.000 description 3
- 208000002894 beriberi Diseases 0.000 description 3
- 210000000038 chest Anatomy 0.000 description 3
- 208000006111 contracture Diseases 0.000 description 3
- 238000007599 discharging Methods 0.000 description 3
- 208000002173 dizziness Diseases 0.000 description 3
- 235000012907 honey Nutrition 0.000 description 3
- 206010022000 influenza Diseases 0.000 description 3
- 210000002429 large intestine Anatomy 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000002175 menstrual effect Effects 0.000 description 3
- 230000004089 microcirculation Effects 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 208000008423 pleurisy Diseases 0.000 description 3
- 206010062261 spinal cord neoplasm Diseases 0.000 description 3
- 229960002117 triamcinolone acetonide Drugs 0.000 description 3
- YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 description 3
- 210000004291 uterus Anatomy 0.000 description 3
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 2
- 229930182837 (R)-adrenaline Natural products 0.000 description 2
- NXJCRELRQHZBQA-UHFFFAOYSA-N 5,7-dimethoxy-1-benzopyran-2-one Chemical compound C1=CC(=O)OC2=CC(OC)=CC(OC)=C21 NXJCRELRQHZBQA-UHFFFAOYSA-N 0.000 description 2
- 240000006409 Acacia auriculiformis Species 0.000 description 2
- 206010063409 Acarodermatitis Diseases 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 2
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 2
- 206010003011 Appendicitis Diseases 0.000 description 2
- 206010003591 Ataxia Diseases 0.000 description 2
- 206010063659 Aversion Diseases 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 206010056377 Bone tuberculosis Diseases 0.000 description 2
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 2
- 206010008531 Chills Diseases 0.000 description 2
- 206010009346 Clonus Diseases 0.000 description 2
- 208000002881 Colic Diseases 0.000 description 2
- 208000034656 Contusions Diseases 0.000 description 2
- 206010010947 Coordination abnormal Diseases 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 206010019799 Hepatitis viral Diseases 0.000 description 2
- 206010019909 Hernia Diseases 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 208000008454 Hyperhidrosis Diseases 0.000 description 2
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 2
- 201000005505 Measles Diseases 0.000 description 2
- 201000009906 Meningitis Diseases 0.000 description 2
- 206010029240 Neuritis Diseases 0.000 description 2
- 206010053658 Pachymeningitis Diseases 0.000 description 2
- 206010033557 Palpitations Diseases 0.000 description 2
- 206010036790 Productive cough Diseases 0.000 description 2
- 208000001431 Psychomotor Agitation Diseases 0.000 description 2
- 208000004680 Rectal Fistula Diseases 0.000 description 2
- 206010038743 Restlessness Diseases 0.000 description 2
- 241000447727 Scabies Species 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- 208000005392 Spasm Diseases 0.000 description 2
- 206010058907 Spinal deformity Diseases 0.000 description 2
- 206010043376 Tetanus Diseases 0.000 description 2
- 206010000269 abscess Diseases 0.000 description 2
- 206010000496 acne Diseases 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 239000003470 adrenal cortex hormone Substances 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- GZCGUPFRVQAUEE-SLPGGIOYSA-N aldehydo-D-glucose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O GZCGUPFRVQAUEE-SLPGGIOYSA-N 0.000 description 2
- 206010002156 anal fistula Diseases 0.000 description 2
- 230000036592 analgesia Effects 0.000 description 2
- 230000000954 anitussive effect Effects 0.000 description 2
- 229940124584 antitussives Drugs 0.000 description 2
- 210000001142 back Anatomy 0.000 description 2
- 230000002146 bilateral effect Effects 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000000812 cholinergic antagonist Substances 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- VRSRXLJTYQVOHC-YEJXKQKISA-N corydaline Chemical compound C=1([C@H]2[C@H]3C)C=C(OC)C(OC)=CC=1CCN2CC1=C3C=CC(OC)=C1OC VRSRXLJTYQVOHC-YEJXKQKISA-N 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 206010061428 decreased appetite Diseases 0.000 description 2
- 230000013872 defecation Effects 0.000 description 2
- 230000000994 depressogenic effect Effects 0.000 description 2
- 208000013219 diaphoresis Diseases 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 201000006549 dyspepsia Diseases 0.000 description 2
- 210000005069 ears Anatomy 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 229960005139 epinephrine Drugs 0.000 description 2
- 231100000321 erythema Toxicity 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000004744 fabric Substances 0.000 description 2
- 239000003337 fertilizer Substances 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 210000003128 head Anatomy 0.000 description 2
- 208000006750 hematuria Diseases 0.000 description 2
- 208000014617 hemorrhoid Diseases 0.000 description 2
- 230000023597 hemostasis Effects 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 235000008216 herbs Nutrition 0.000 description 2
- 230000003118 histopathologic effect Effects 0.000 description 2
- 238000001794 hormone therapy Methods 0.000 description 2
- 208000016290 incoordination Diseases 0.000 description 2
- 230000030214 innervation Effects 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 229960004194 lidocaine Drugs 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 208000030208 low-grade fever Diseases 0.000 description 2
- 201000003453 lung abscess Diseases 0.000 description 2
- 201000007227 lymph node tuberculosis Diseases 0.000 description 2
- 210000004914 menses Anatomy 0.000 description 2
- 230000005906 menstruation Effects 0.000 description 2
- 230000001617 migratory effect Effects 0.000 description 2
- 208000004296 neuralgia Diseases 0.000 description 2
- 206010029410 night sweats Diseases 0.000 description 2
- 230000036565 night sweats Effects 0.000 description 2
- 229940100691 oral capsule Drugs 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 206010034754 petechiae Diseases 0.000 description 2
- 210000003800 pharynx Anatomy 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000007670 refining Methods 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 201000005404 rubella Diseases 0.000 description 2
- 208000005687 scabies Diseases 0.000 description 2
- 230000001932 seasonal effect Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000002689 soil Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 235000014347 soups Nutrition 0.000 description 2
- 230000002048 spasmolytic effect Effects 0.000 description 2
- 210000003594 spinal ganglia Anatomy 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000035922 thirst Effects 0.000 description 2
- 210000003448 thoracic nerve Anatomy 0.000 description 2
- 208000037816 tissue injury Diseases 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 231100000820 toxicity test Toxicity 0.000 description 2
- 229940126680 traditional chinese medicines Drugs 0.000 description 2
- 241001529453 unidentified herpesvirus Species 0.000 description 2
- 210000003932 urinary bladder Anatomy 0.000 description 2
- 201000001862 viral hepatitis Diseases 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- 235000014101 wine Nutrition 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- 239000001100 (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one Substances 0.000 description 1
- UUTKICFRNVKFRG-WDSKDSINSA-N (4R)-3-[oxo-[(2S)-5-oxo-2-pyrrolidinyl]methyl]-4-thiazolidinecarboxylic acid Chemical compound OC(=O)[C@@H]1CSCN1C(=O)[C@H]1NC(=O)CC1 UUTKICFRNVKFRG-WDSKDSINSA-N 0.000 description 1
- XUCIJNAGGSZNQT-JHSLDZJXSA-N (R)-amygdalin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O[C@@H](C#N)C=2C=CC=CC=2)O1 XUCIJNAGGSZNQT-JHSLDZJXSA-N 0.000 description 1
- FLNXBVJLPJNOSI-UHFFFAOYSA-N 1-[2-[(4-chlorophenyl)-phenylmethoxy]ethyl]piperidine Chemical compound C1=CC(Cl)=CC=C1C(C=1C=CC=CC=1)OCCN1CCCCC1 FLNXBVJLPJNOSI-UHFFFAOYSA-N 0.000 description 1
- 244000296912 Ageratum conyzoides Species 0.000 description 1
- 235000004405 Ageratum conyzoides Nutrition 0.000 description 1
- ATWHGWYKSFRYBN-UHFFFAOYSA-N Amygdaloside Natural products O1C(=O)C2(C)CCCC(C3CC4)(C)C2C1OCC3(C1)CC4C1(O)COC1OC(CO)C(O)C(O)C1O ATWHGWYKSFRYBN-UHFFFAOYSA-N 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 241000203233 Aspergillus versicolor Species 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 208000019838 Blood disease Diseases 0.000 description 1
- 241000717739 Boswellia sacra Species 0.000 description 1
- 235000016535 Capraria biflora Nutrition 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000001387 Causalgia Diseases 0.000 description 1
- 206010007882 Cellulitis Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 241000905957 Channa melasoma Species 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 208000023890 Complex Regional Pain Syndromes Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- VRSRXLJTYQVOHC-UHFFFAOYSA-N Corydaline Natural products CC1C2C=3C=C(OC)C(OC)=CC=3CCN2CC2=C1C=CC(OC)=C2OC VRSRXLJTYQVOHC-UHFFFAOYSA-N 0.000 description 1
- 241001427554 Corydiidae Species 0.000 description 1
- 241001269238 Data Species 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 206010012218 Delirium Diseases 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 206010014080 Ecchymosis Diseases 0.000 description 1
- 206010015137 Eructation Diseases 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 241001489980 Eupolyphaga sinensis Species 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 206010052140 Eye pruritus Diseases 0.000 description 1
- 206010055690 Foetal death Diseases 0.000 description 1
- 239000004863 Frankincense Substances 0.000 description 1
- 206010017553 Furuncle Diseases 0.000 description 1
- UTPGJEROJZHISI-DFGCRIRUSA-N Gaillardin Chemical compound C1=C(C)[C@H]2[C@@H](OC(=O)C)C[C@@](C)(O)[C@@H]2C[C@@H]2C(=C)C(=O)O[C@H]21 UTPGJEROJZHISI-DFGCRIRUSA-N 0.000 description 1
- 208000012895 Gastric disease Diseases 0.000 description 1
- 241000501743 Gentiana macrophylla Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 206010019468 Hemiplegia Diseases 0.000 description 1
- 208000000616 Hemoptysis Diseases 0.000 description 1
- 206010019668 Hepatic fibrosis Diseases 0.000 description 1
- QUQPHWDTPGMPEX-UHFFFAOYSA-N Hesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(COC4C(C(O)C(O)C(C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-UHFFFAOYSA-N 0.000 description 1
- 235000017309 Hypericum perforatum Nutrition 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000015817 Infant Nutrition disease Diseases 0.000 description 1
- 206010022067 Injection site haemorrhage Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 108010025252 Kassinin Proteins 0.000 description 1
- 206010023644 Lacrimation increased Diseases 0.000 description 1
- 206010024453 Ligament sprain Diseases 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 241001448624 Miliaria Species 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 239000008896 Opium Substances 0.000 description 1
- 235000019082 Osmanthus Nutrition 0.000 description 1
- 241000333181 Osmanthus Species 0.000 description 1
- 241000590428 Panacea Species 0.000 description 1
- 240000005373 Panax quinquefolius Species 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- UTPGJEROJZHISI-UHFFFAOYSA-N Pleniradin-acetat Natural products C1=C(C)C2C(OC(=O)C)CC(C)(O)C2CC2C(=C)C(=O)OC21 UTPGJEROJZHISI-UHFFFAOYSA-N 0.000 description 1
- 206010068676 Pneumoretroperitoneum Diseases 0.000 description 1
- 208000037062 Polyps Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 241000219780 Pueraria Species 0.000 description 1
- 208000005727 Retropneumoperitoneum Diseases 0.000 description 1
- 206010039101 Rhinorrhoea Diseases 0.000 description 1
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000010040 Sprains and Strains Diseases 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 101000874347 Streptococcus agalactiae IgA FC receptor Proteins 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 229930183118 Tanshinone Natural products 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- 241000130764 Tinea Species 0.000 description 1
- 208000002474 Tinea Diseases 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 206010044302 Tracheitis Diseases 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 208000036029 Uterine contractions during pregnancy Diseases 0.000 description 1
- 206010046788 Uterine haemorrhage Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 208000000260 Warts Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 201000004484 acute conjunctivitis Diseases 0.000 description 1
- 210000004404 adrenal cortex Anatomy 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000001088 anti-asthma Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001166 anti-perspirative effect Effects 0.000 description 1
- 230000001139 anti-pruritic effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 239000000924 antiasthmatic agent Substances 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 239000003213 antiperspirant Substances 0.000 description 1
- 239000003908 antipruritic agent Substances 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- QUQPHWDTPGMPEX-UTWYECKDSA-N aurantiamarin Natural products COc1ccc(cc1O)[C@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1 QUQPHWDTPGMPEX-UTWYECKDSA-N 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 208000034526 bruise Diseases 0.000 description 1
- 239000008338 calamine lotion Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 235000019994 cava Nutrition 0.000 description 1
- 230000003727 cerebral blood flow Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 201000001883 cholelithiasis Diseases 0.000 description 1
- APSNPMVGBGZYAJ-GLOOOPAXSA-N clematine Natural products COc1cc(ccc1O)[C@@H]2CC(=O)c3c(O)cc(O[C@@H]4O[C@H](CO[C@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@H]5O)[C@@H](O)[C@H](O)[C@H]4O)cc3O2 APSNPMVGBGZYAJ-GLOOOPAXSA-N 0.000 description 1
- 229960002544 cloperastine Drugs 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 208000014439 complex regional pain syndrome type 2 Diseases 0.000 description 1
- 230000002153 concerted effect Effects 0.000 description 1
- 210000000795 conjunctiva Anatomy 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000009519 contusion Effects 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 239000003218 coronary vasodilator agent Substances 0.000 description 1
- 231100000895 deafness Toxicity 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 201000005619 esophageal carcinoma Diseases 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 210000000887 face Anatomy 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 229940085771 feverall Drugs 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 206010016766 flatulence Diseases 0.000 description 1
- 229930182486 flavonoid glycoside Natural products 0.000 description 1
- 150000007955 flavonoid glycosides Chemical class 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 208000003512 furunculosis Diseases 0.000 description 1
- 238000005247 gettering Methods 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 238000009499 grossing Methods 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000016354 hearing loss disease Diseases 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- VUYDGVRIQRPHFX-UHFFFAOYSA-N hesperidin Natural products COc1cc(ccc1O)C2CC(=O)c3c(O)cc(OC4OC(COC5OC(O)C(O)C(O)C5O)C(O)C(O)C4O)cc3O2 VUYDGVRIQRPHFX-UHFFFAOYSA-N 0.000 description 1
- 229940025878 hesperidin Drugs 0.000 description 1
- QUQPHWDTPGMPEX-QJBIFVCTSA-N hesperidin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]4[C@@H]([C@H](O)[C@@H](O)[C@H](C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-QJBIFVCTSA-N 0.000 description 1
- 208000021760 high fever Diseases 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 210000003026 hypopharynx Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000002917 insecticide Substances 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000000622 irritating effect Effects 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000004317 lacrimation Effects 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 229940025300 lidocaine injection Drugs 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 208000004396 mastitis Diseases 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 208000007106 menorrhagia Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 208000010753 nasal discharge Diseases 0.000 description 1
- ARGKVCXINMKCAZ-UHFFFAOYSA-N neohesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(CO)O3)OC3C(C(O)C(O)C(C)O3)O)=CC(O)=C2C(=O)C1 ARGKVCXINMKCAZ-UHFFFAOYSA-N 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 239000000820 nonprescription drug Substances 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 229960001027 opium Drugs 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 238000000643 oven drying Methods 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000003119 painkilling effect Effects 0.000 description 1
- 230000032696 parturition Effects 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 238000000554 physical therapy Methods 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 230000001047 pyretic effect Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 229910052957 realgar Inorganic materials 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 201000010153 skin papilloma Diseases 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 230000035943 smell Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000021595 spermatogenesis Effects 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 238000001256 steam distillation Methods 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 210000001562 sternum Anatomy 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 208000018556 stomach disease Diseases 0.000 description 1
- 230000004206 stomach function Effects 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 230000002537 thrombolytic effect Effects 0.000 description 1
- 229940098465 tincture Drugs 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 206010044008 tonsillitis Diseases 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 210000001113 umbilicus Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000003639 vasoconstrictive effect Effects 0.000 description 1
- 210000000264 venule Anatomy 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- CPYIZQLXMGRKSW-UHFFFAOYSA-N zinc;iron(3+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[O-2].[Fe+3].[Fe+3].[Zn+2] CPYIZQLXMGRKSW-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
本发明提供一种治疗肋间神经痛的中药组合物,内服药物为:当归10~20份,黄芪10~20份,丹参10~20份,桃仁10~20份,红花10~20份,香附10~20份,白芍10~20份,鸡血藤10~20份,川芎10~20份,熟地10~20份,佛手10~20份,莪术10~20份,秦艽10~20份,柴胡10~20份,郁金10~20份,旋覆花10~20份;外用药物为:鸡血藤10~20份,川芎10~20份,赤芍10~20份,防风10~20份,白及10~20份,白芷10~20份,当归10~20份,延胡索10~20份,荆芥10~20份,丹参10~20份,威灵仙10~20份,土鳖虫10~20份,地龙10~20份。本发明中药组合物配伍合理,具有强而持久抗炎作用,能抑制感染性和非感染性炎症,减轻充血、降低毛细血管的通透性,抑制炎症细胞等发生反应,抑制吞噬细胞的功能,稳定溶酶体膜,阻止补体参与炎症反应,抑制炎症后组织损伤的修复。
Description
技术领域
本发明涉及含有来源于植物、动物或矿物组份的医用配制品,特别涉及一种治疗肋间神经痛的中药组合物及其制备方法。
背景技术
肋间神经痛是一组症状,指胸神经根(即肋间神经)由于不同原因的损害,如:胸椎退变、胸椎结核、胸椎损伤、胸椎硬脊膜炎、肿瘤、强直性脊柱炎等疾病或肋骨、纵膈、胸膜病变,肋间神经受到上述疾病产生的压迫、刺激,出现炎性反应,而出现以胸部肋间或腹部呈带状疼痛的综合征。
肋间神经痛是指一个或几个肋间部位发生的经常性疼痛,并有发作性加剧。原发性肋间神经痛极少见,继发性者多与病毒感染,毒素刺激,机械损伤及异物压迫等有关。其疼痛性质多为刺痛或灼痛,并沿肋间神经分布。
肋间神经痛是指一根或几根肋间神经支配区的经常性疼痛。它是老年人常见的胸痛原因之一。我们知道,肋间神经共有12对,由胸髓发出后经前根和后根联合而组成。胸神经分为前支、后支、脊膜支和交通支。前支位于肋间内、外侧肌之间叫做肋间神经,走行在肋间动脉的下面。临床上通常见到的是继发性肋间神经痛,而原发性肋间神经痛较少见。继发性肋间神经痛是由邻近器官和组织的病变引起,如胸腔器官的病变(胸膜炎、慢性肺部炎症、主动脉瘤等),脊柱和肋骨的损伤,老年性脊椎骨性关节炎,胸椎段脊柱的畸形,胸椎段脊髓肿瘤,特别是髓外瘤,常压迫神经根而有肋间神经痛的症状。还有一种带状疱疹病毒引起的肋间神经炎,也可出现肋间神经痛。肋间神经痛主要为一个或几个肋间的经常性疼痛,时有发作性加剧,有时被呼吸动作所激发,咳嗽、喷嚏时疼痛加重。疼痛剧烈时可放射至同侧的肩部或背部,有时呈带状分布。检查时可发现相应皮肤区的感觉过敏和相应肋骨边缘压痛,于肋间神经穿出椎间孔后在背部、胸侧壁、前胸穿出处尤为显著。有些病人可发现各种原发病变的相应症状和体征。
另外,带状疱疹病毒性神经炎引起的肋间神经痛是指疱疹病毒侵犯皮肤及背根神经节,在其神经支配区的皮肤上产生成群的水疱和丘疹,而以水疱为多见,按肋间神经分布排列呈带状,同时伴有一个或几个邻近肋间神经分布区的神经痛。发病时有低热、疲倦、食欲不振等前驱症状,继而局部出现感觉过敏、烧灼感或程度不等的胸腹壁深部疼痛。继发性肋间神经痛的治疗须视病因而定。原发性肋间神经痛可按神经痛的一般疗法治疗,如各种止痛剂的使用、理疗等。当无效时可考虑肋间神经根部封闭。对于带状疱疹的皮肤损害可对外用保护干燥剂,如樟脑扑粉、炉甘石洗剂或龙胆紫溶液,5%雄黄酊外用亦有消炎止痛作用;适当使用维生素B1、B12和肾上腺皮质激素常有良好的效果。
咳嗽、喷嚏时疼痛加重。疼痛剧烈时可放射至同侧的肩部或背部,有时呈带状分布。检查时可发现相应皮肤区的感觉过敏和相应肋骨边缘压痛,于肋间神经穿出椎间孔后在背部、胸侧壁、前胸穿出处尤为显著。有些病人可发现各种原发病变的相应症状和体征。对于经常性疼痛,舒肋.消.肿膏具有消肿止痛的功效。另外,带状疱疹病毒性神经炎引起的肋间神经痛是指疱疹病毒侵犯皮肤及背根神经节,在其神经支配区的皮肤上产生成群的水疱和丘疹,而以水疱为多见,按肋间神经分布排列呈带状,同时伴有一个或几个邻近肋间神经分布区的神经痛。发病时有低热、疲倦、食欲不振等前驱症状,继而局部出现感觉过敏、烧灼感或程度不等的胸腹壁深部疼痛。
肋间神经痛分继发性和原发性两种,由胸椎退变、胸椎结核、胸椎损伤、胸椎硬脊膜炎、肿瘤、强直性脊柱炎等疾病可继发根性的肋间神经痛;肋骨、纵膈或胸膜病变会继发干性的肋间神经痛。原发性的肋间神经痛少见。肋间神经痛发病时,可见疼痛由后向前,沿相应的肋间隙放射呈半环形;疼痛呈刺痛或烧灼样痛。咳嗽、深呼吸或打喷嚏时疼痛加重。疼痛多发于一侧的一支神经。体检发现,胸椎棘突旁和肋间隙有明显压痛;典型的根性肋间神经痛患者,屈颈试验阳性;受累神经的分布区常有感觉过敏或感觉减退等神经功能损害表现。
中医将肋间神经痛列为“胸肋骨痹”的范畴。认为该病的形成有内、外两大因素。内因为气血虚弱,营卫表里不和,阴阳失调、筋骨失养;外因则是偶尔胸肋部闪挫,风寒湿邪入侵,瘀滞筋骨,阻塞脉络,致气血运行不通所致。气滞血瘀,风热入侵经络,毒热交炽,气血壅遏不通,不通则痛。肋间神经痛呈急性发病,可反复发作,时有发作性加剧。急诊病人因发病急,发作时疼痛剧烈,就诊时均希望能在短时间内缓解疼痛,但本病暂无理想的特效治疗。西药一般采取注射止疼剂,或激素治疗,缓解疼痛迅速,但持久性稳定性差,治标不治本。中药方剂随证加减,没有特定针对性,并且缓慢,见效慢,病患痛苦时间长,病患不易坚持。
发明内容
本发明所要解决的技术问题在于,针对本病急诊病人因发病急,发作时疼痛剧烈,就诊时均希望能在短时间内缓解疼痛,但本病暂无理想的特效治疗。西药一般采取注射止疼剂,或激素治疗,缓解疼痛迅速,但持久性稳定性差,治标不治本。中药方剂随证加减,没有特定针对性,并且缓慢,见效慢,病患痛苦时间长,病患不易坚持;中药内服制剂和外用制剂的共同不足之处是,药效持续时间较短,针对性比较差,病患服从性差。
为解决这些技术难题,本发明提供了一种治疗肋间神经痛的中药组合物,由内服药物和外用药物组成,所述内服药物中各种原料的重量份数为:当归10~20份,黄芪10~20份,丹参10~20份,桃仁10~20份,红花10~20份,香附10~20份,白芍10~20份,鸡血藤10~20份,川芎10~20份,熟地10~20份,佛手10~20份,莪术10~20份,秦艽10~20份,川芎10~20份,柴胡10~20份,郁金10~20份,旋覆花10~20份;
外用药物中各种原料的重量份数为:鸡血藤10~20份,川芎10~20份,赤芍10~20份,防风10~20份,白及10~20份,白芷10~20份,当归10~20份,延胡索10~20份,荆芥10~20份,丹参10~20份,威灵仙10~20份,土鳖虫10~20份,地龙10~20份。
所述治疗肋间神经痛的中药组合物,其所述内服药物中各种原料的重量份数可以为:当归10~15份,黄芪10~15份,丹参10~15份,桃仁10~15份,红花10~15份,香附10~15份,白芍10~15份,鸡血藤10~20份,川芎10~20份,熟地10~20份,佛手10~20份,莪术10~20份,秦艽10~20份,川芎10~20份,柴胡10~20份,郁金10~20份,旋覆花10~20份;
外用药物中各种原料的重量份数可以为:鸡血藤10~15份,川芎10~15份,赤芍10~15份,防风10~15份,白及10~15份,白芷10~15份,当归10~20份,延胡索10~20份,荆芥10~20份,丹参10~20份,威灵仙10~20份,土鳖虫10~20份,地龙10~20份。
所述治疗肋间神经痛的中药组合物,其所述内服药物中各种原料的重量份数还可以为:当归10~20份,黄芪10~20份,丹参10~20份,桃仁10~20份,红花10~20份,香附10~20份,白芍10~20份,鸡血藤10~15份,川芎10~15份,熟地10~15份,佛手10~15份,莪术10~15份,秦艽10~15份,川芎10~15份,柴胡10~15份,郁金10~15份,旋覆花10~15份;
外用药物中各种原料的重量份数还可以为:鸡血藤10~20份,川芎10~20份,赤芍10~20份,防风10~20份,白及10~20份,白芷10~20份,当归10~15份,延胡索10~15份,荆芥10~15份,丹参10~15份,威灵仙10~15份,土鳖虫10~15份,地龙10~15份。
为解决上述技术问题,本发明还提供一种治疗肋间神经痛的中药组合物的制备方法,其所述内服制剂的剂型为胶囊剂,其制备方法包括:
a、取原料药放入乙醇中浸泡,热提取2次,成膏状,为组分1;
b、药渣加水提取2次,浓缩过滤为膏状,为组分2;
c、将上述两种膏状合并,浓缩成粉末装入胶囊。
所述步骤a中,可以取原料药加入5-10倍量的乙醇中浸泡1-2小时,加热提取2次,每次1-2小时,合并提取液,静置后去上清液,然后100-120目滤过,再经截流分子量为5000-10000的超滤柱超滤,超滤液减压浓缩相对密度为80℃时1.36的浸膏,静置备用,成为组分1。
所述步骤b中,可以将上述乙醇提取过的原料药的药渣加10倍量水,加热回流提取2次,每次1~2小时,将2次提取液合并静置;将上述两种提取液合并,减压回收乙醇并浓缩至药液浓度为0.6g生药/mL,抽滤后,滤液的相对密度约为20℃时1.08;浓缩至相对密度为1.20,温度至60℃-70℃的浸膏,静置备用,成为组分2。
所述步骤c中,可以将组分1和组分2的浸膏合并,然后放入减压浓缩罐内,减压浓缩至相对密度为1.20,然后取出,放入烘干机烘干成粉末,放入胶囊中,成胶囊剂。
为解决上述技术问题,本发明再提供一种治疗肋间神经痛的中药组合物的制备方法,所述内服制剂的剂型为丸剂,制备方法包括:
将所述组份原料药去杂,晾干,粉碎成颗粒,加水浸泡1小时;将浸泡好的原料置多功能提取罐中加水煎煮二次;第一次加总药材10倍量的水,煎煮1.5~2小时,取煎液,滤过;第二次加总量7倍量的水,煎煮1~1.2小时,取两次煎液混合,滤过;将过滤的滤液置入双效真空浓缩器中,浓缩至90℃时相对密度为1.05的浓缩液,置0~5℃低温冷藏24小时;将冷藏液加0.3%的助滤剂硅藻土,过滤,滤液再置入双效真空浓缩器中,浓缩至每1ml含1g生药量,直接干燥成粉末;然后加蜂蜜搓成丸剂。
为解决上述技术问题,本发明也提供一种治疗肋间神经痛的中药组合物的制备方法,所述外用制剂的剂型为膏剂的制备方法包括以下步骤:
按照所述份数先将白芷、防风、和白及水蒸气法蒸馏,得到结晶物,作为组分1备用;取蒸馏后的药渣混合剩余原料加入5-10倍量的60-90%乙醇浸泡1-2小时,加热提取2次,每次1-2小时,去上清液,合并提取液,80-120目滤过,再经截流分子量为5000-10000的超滤柱超滤,超滤液减压浓缩相对密度为80℃时1.36的浸膏,加热浓缩,30分钟~45分钟,将浓缩液静置成浸膏状,药糊继续加热浓缩至浸膏状,静置备用,成为组分2;将蒸馏提取的组分1和乙醇提取的组分2混合,加凡士林成膏剂。
所述治疗治疗肋间神经痛的中药组合物,所述组合物的内服药物剂型可以为:糖衣片剂、薄膜衣片剂、肠溶衣片剂、硬胶囊剂、软胶囊剂、口服液、口含剂、颗粒剂、冲剂、丸剂、散剂、丹剂、溶液剂或注射剂;所述组合物的外用药物剂型可以为:喷雾剂、粉剂、散剂、软膏剂、纱布剂或贴膏剂。
对于肋间神经痛,西药目前没有明显针对性的用药,治疗上多以单纯注射止疼或激素止疼治疗。而中医在治疗此类病证的效果上是具有明显优势,本发明内服外用共同作用,能直达病灶,燥湿除脓、温补肾阳,益肾填精,滋补肾阴,益精养血;舒肝理气,补肾益精及清热利湿等。本发明中药组合物配伍合理,具有强而持久抗炎作用,能抑制感染性和非感染性炎症,减轻充血、降低毛细血管的通透性,抑制炎症细胞等发生反应,抑制吞噬细胞的功能,稳定溶酶体膜,阻止补体参与炎症反应,抑制炎症后组织损伤的修复。其毒副作用小,使用方便,治愈时间短,治愈后不易复发。能创造较好的社会价值及经济利益。
具体实施方式
本病属于祖国医学的“胁痛”范畴。《灵枢·经脉篇》说:“肝、足厥阴之脉......属肝,络胆,......布胁肋。”“胆、足少阳之脉,络肝,属胆,循胁里......其直者,从缺盆下腋,循胸过季胁。”又《五邪篇》说:“邪在肝,则两胁中痛......”《邪气藏府病形篇》说:“有所堕坠,恶血留内,若有所大怒,气上而不下,积于胁下,则伤肝。”《丁甘仁医案·脘胁痛)黎右案说:“胁乃肝之分野,肝气入络,胁痛偏左......”都指出了胸胁部位是肝、胆所分布之处,故胸胁部的疼痛与肝胆二经的功能失调有一定的关系。同时说明堕坠(括跌扑损伤)则恶血积于胁下,大怒则怒气积于胁下是二种可以引起胁痛的原因。《临症指南医案-胁痛门》汪案说:“痛在胁肋,游走不定......。”指出了胸胁痛两侧均能发生,亦与现代所见的肋间神经痛一症相符。临床所见单纯的肋间神经痛,其病因主要不外肝气郁结、痰血停着,如负重逆气,或用力过猛(劳损刺激肋间神经、机械性的刺激、劳动后组织代谢产生酸性产物如乳酸等)等所引起的肋软骨与胸骨之间的动作失调所致。亦有并无前述病史,却由于肋软骨局部积劳日久,偶受轻微压力或咳嗽,因而引起该处伤损而突然发生本症。在中医方面的治疗上,舒肋.消肿.膏针对肋间神经痛的症状,可以进行很好的治疗。根据四总穴歌“胁肋支沟取,心胸内关谋”,故以内关为主穴,配太冲可疏肝理气;三阴交为足三阴之交会穴,能活血祛瘀;胁肋部为足少阳胆经所过,肝胆相表里,肝脉布胁肋。阳陵泉穴为足少阳胆经穴,为足少阳经合穴,又为八脉交会穴之一,及“筋会”,刺之可疏肝利胆,疏通经络。
肋间神经痛又称肋间神经炎,实际上仅仅是一种症状的名称,分原发性和继发性两种,临床上以继发性肋间神经痛多见,原发性肋间神经痛较少见。
继发性肋间神经痛是由邻近器官和组织病变引起,如胸腔器官病变(胸膜炎、慢性肺部炎症、主动脉瘤等)、脊柱和肋骨的损伤、老年性脊椎骨性关节炎、胸椎段脊柱畸形、胸椎段脊髓肿瘤,常压迫神经根而出现症状,带状疱疹病毒引起的肋间神经炎,也可出现肋间神经痛。带状疱疹引起的肋间神经痛因局部确定固定压痛点困难,对有皮疹及局部皮肤感染者未使用该方法。对于肋间神经痛的治疗,中医使用外用药膏剂、针刺配合中药、穴位刺络拔罐、电针等治疗获得满意疗效。但从方便快捷方面看,西医可能更适合急诊病人。但不会治本。
黄芪以补虚为主,能补气固表,利尿托毒,排脓,敛疮生肌。用于气血不足、疮疡内陷、脓成不溃或久溃不敛者。黄芪具有很好的托毒生肌的功能,即久不愈合的脓肿化脓生肌。现代医学研究表明,黄芪内含而多种抗菌有效成分,而且能增强机体的免疫功能,因此还能用于预防某些传染病的发生。《本草逢原》载:“黄芪能补五脏诸虚,治脉弦自汗,泻阴火,去肺热,无汗则发,有汗则止。”是增进抵抗力和防御疾病的良药。
当归,其味甘而重,故专能补血,其气轻而辛,故又能行血,补中有动,行中有补,诚血中之气药,亦血中之圣药。大约佐之以补则补,故能养营养血,补气生精,安五脏,强形体,益神志,凡有形虚损之病,无所不宜。佐之以攻则通,故能祛痛通便,利筋骨,治拘挛、瘫痪、燥、涩等证。营虚而表不解者,佐以柴、葛、麻、桂等剂,大能散表卫热,而表不敛者,佐以大黄之类,又能固表。惟其气辛而动,故欲其静者当避之,性滑善行,大便不固者当避之。凡阴中火盛者,当归能动血,亦非所宜,阴中阳虚者,当归能养血,乃不可少。
川芎辛,温。入肝、胆经。行气开郁,法风燥湿,活血止痛。治风冷头痛旋晕,胁痛腹疼,寒痹筋挛,经闭,难产,产后瘀阻块痛,痈疽疮疡。用于月经不调,经闭痛经,瘕腹痛,胸胁刺痛,跌扑肿痛,头痛,风湿痹痛。《本经》载其:主中风入脑头痛,寒痹,筋挛缓急,金创,妇人血闭无子。《别录》载其:″除脑中冷动,面上游风去来,目泪出,多涕唾,忽忽如醉,诸寒冷气,心腹坚痛,中恶,卒急肿痛,胁风痛,温中内寒。″是行气化瘀的良药
丹参苦,微寒。归心、肝经。祛瘀止痛,活血通经,清心除烦。用于月经不调,经闭痛经,症瘕积聚,胸腹刺痛,热痹疼痛,疮疡肿痛,心烦不眠。用于胸肋胁痛,风湿痹痛,症瘕结块,疮疡肿痛,跌仆伤痛,月经不调,经闭痛经,产后瘀痛等。治疗胸肋疼痛、症瘕结块,以及月经不调、经闭经痛具有良效。.《纲目》载:丹参,按《妇人明理论》云,四物汤治妇人病,不问产前产后,经水多少,皆可通用,惟一味丹参散,主治与之相同。盖丹参能破宿血,补新血,安生胎,落死胎,止崩中滞下,调经脉。丹参主要成分丹参酮有扩张血管、改善循环、解除血管内凝血等作用,具有活血化痕之功效,并能促进肝脏血液循环,利于肝细胞再生。
秦艽是中国重要的传统中药之一,始载于《神农本草经》,列为中品,用于风湿痹痛,筋脉拘挛,骨节酸痛,日晡潮热,小儿疳积发热。“秦艽主寒热邪气,寒湿风痹,肢节痛、下水、利小便。”《名医别录》称“秦艽能疗风,无问久新,通身挛急”。李时珍也指出“秦艽出秦中,以根作罗纹相交者为佳,故名秦艽,秦纠”。所以四种正品原植物中以大叶秦艽最为重要,作为秦艽药用历史悠久,并且处于黄土高原腹地的陕西、甘肃两省是其地道产区。秦艽是中药治疗风湿痹痛,关节病必不可少的药物。
熟地又名熟地黄或伏地,属玄参科植物,是一种上好中药材,具有补血滋阴功效,可用于血虚萎黄,眩晕,心悸失眠,月经不调,崩漏等症,亦可用于肾阴不足的潮热骨蒸、盗汗、遗精、消渴等症,是虚证类非处方药药品六味地黄丸主要成分之一。本品质润入肾,善滋补肾阴,填精益髓,为补肾阴之要药。古人谓之“大补五脏真阴”,“大补真水”。常与山药、山茱萸等同用,治疗肝肾阴虚,腰膝酸软、遗精、盗汗、耳鸣、耳聋及消渴等,可补肝肾,益精髓,如六味地黄丸。
红花性温,味辛。功能主治应用于活血通径、散瘀止痛。用于经闭、痛经、恶露不行、症瘕痞块、跌打损伤。《本草汇言》:红花,破血、行血、和血、调血之药也。主胎产百病因血为患,或血烦血晕,神昏不语;或恶露抢心,脐腹绞痛;或沥浆难生,;或胞衣不落,子死腹中,是皆临产诸证,非红花不能治。若产后血晕、口噤指搦;或邪入血室,谵语发狂;或血闷内胀,僵仆如死,是皆产后诸证,非红花不能定。凡如经闭不通而寒热交作,或过期腹痛而紫黑淋漓,或跌扑损伤而气血瘀积,或疮疡痛痒而肿溃不安,是皆气血不和之证,非红花不能调,红花活血通经、消肿止痛,有抑制血栓形成、抗炎、止痛作用,具有消除肾上腺素、去甲肾上腺素的收缩血管作用,有“通利经脉”作用。
莪术辛、苦,温。归肝、脾经。破血行气止痛:本品功效与三棱相似,但温通力较大,可治疗血滞经闭腹痛、腹部包块、积聚。积散结:本品能行气消积止痛,用于饮食积滞、胸腹满闷作痛。破血祛瘀,妇女闭经,或痰湿淤血凝结而成的症瘕癖块。行气止痛:适于饮食失调,脘腹涨满疼痛之证。适当配伍,虚症、实症均可。
桃仁苦、甘,平。归心、肝、大肠经。功能主治:活血祛瘀,润肠通便,止咳平喘。用于经闭,痛经,癓瘕痞块,跌扑损伤,肠燥便秘。桃仁提取液能明显增加脑血流量,增加犬股动脉的血流量,降低血管阻力,改善血流动力学状况。提取物能改善动物的肝脏表面微循环,并促进胆汁分泌。桃仁可使小鼠的出血及凝血时间明显延长,煎剂对体外血栓有抑制作用,水煎液有纤维促进作用。桃仁中含45%的脂肪油可润滑肠道,利于排便。桃仁能促进初产妇子宫收缩及出血。水煎剂及提取物有镇痛、抗炎、抗菌、抗过敏作用。桃仁中的苦杏仁苷有镇咳平喘及抗肝纤维化的作用。桃仁味苦甘而性平,能入心、肝、大肠,活血祛瘀作用甚广,可用治瘀血阻滞各种敝症。在治疗方面,善于治疗内痈,如肺痈;肠痈每持为要要药,是其具特有之性能欤。脂多质润,具润肠通便之功,唯晚近临床专以润肠通便则较少用。月经过多及孕妇忌用。桃仁与红花皆为活血祛瘀之药,作用均甚广泛,往往配合应用,唯桃仁善治肺痈肠痈,且有润肠通便之效;红花则善于活血调经。
郁金理气解郁,调经止痛。用于肝郁气滞,胸、胁、脘腹胀痛,消化不良,月经不调,经闭痛经,寒疝腹痛,乳房胀痛。理气解郁:用于肝气郁结之胸胁及胃腹胀痛。《纲目》载其:散时气寒疫,利三焦,解六郁,消饮食积聚,痰饮痞满,跗肿,腹胀,脚气,止心腹、肢体、头、目、齿、耳诸痛,痈疽疮疡,吐血,下血,尿血,妇人崩漏带下,月候不调,胎前产后百病。
柴胡清虚热中药,用于感冒发热、寒热往来、疟疾、肝郁气滞、胸肋胀痛、脱肛、子宫脱落、月经不调。归肝经、胆经。功能:疏散退热,升阳舒肝。主治:感冒发热、寒热往来、疟疾,肝郁气滞,胸肋胀痛,脱肛,子宫脱落,月经不调。治疗病毒性肝炎:柴胡注射液(每1ml含生药2g)10~20ml加入50%葡萄糖液静注或5%葡萄糖液250~500ml静滴,每日1次,10次为1疗程,治疗病毒性肝炎120例,其中急性病例97例,有效率为98.4%;慢性病例23例,有效率为100%,对改善症状、回缩肝脾、恢复肝功及乙肝抗原阴转率均有较好作用。
佛手不仅有较高的观赏价值,而且具有珍贵的药用价值、经济价值。佛手全身都是宝,其根、茎、叶、花、果均可入药,辛、苦、甘、温、无毒,入肝、脾、胃三经,有理气化痰,止咳消胀、舒肝健脾和胃等多种药用功能。据史料记载,佛手的根可治男人下消、四肢酸软;花、果可泡茶,有消气作用;果可治胃病、呕吐、噎嗝、高血压、气管炎、哮喘等病症。据《归经》等载,佛手并具治鼓胀发肿病,妇女白带病及醒酒作用,是配制佛手中成药的主要原料。佛手不仅有较高的观赏价值,而且具有珍贵的药用价值。李时珍在《本草纲目》中记载:“佛手气味辛,温无毒;主治下气,除心头痰水;煮酒饮,治痰多咳漱;煮汤,治心下气痛。”佛手全身都是宝,根、茎、叶、花、果均可入药,性味辛、甘、苦、温、无毒,入肝、脾、胃、肺经,有疏肝解郁、燥湿化痰、理气和中的功效,常用于肝郁气滞、脾胃气滞和痰湿壅肺等证。药理研究表明,佛手主要含柠檬油素等香豆精类,尚含黄酮苷、橙皮苷、有机酸、挥发油等,对肠道平滑肌有明显的抑制作用,对乙酰胆碱引起的十二指肠痉挛有明显的解痉作用,可扩张冠状血管,增加冠脉的血流量,减缓心率和降低血压。
香附辛微苦甘,平功能主治:理气解郁,调经止痛。用于肝郁气滞,胸、胁、脘腹胀痛,消化不良,月经不调,经闭痛经,寒疝腹痛,乳房胀痛。《纲目》载其:散时气寒疫,利三焦,解六郁,消饮食积聚,痰饮痞满,跗肿,腹胀,脚气,止心腹、肢体、头、目、齿、耳诸痛,痈疽疮疡,吐血,下血,尿血,妇人崩漏带下,月候不调,胎前产后百病。
旋覆花:味苦;辛;咸;微温。归肺;胃;大肠经。降气,消痰,行水,止呕。用于风寒咳嗽,痰饮蓄结,胸膈痞满,喘咳痰多,呕吐噫气。《神农本草经》:“主结气胁下满,惊悸。除水,去五脏间寒热,补中,下气。”现代研究,旋覆花对免疫性肝损伤有保护作用,其化学成分天人菊内酯有抗癌作用。此外,其根及茎叶或地上部分亦可入药,治刀伤、疔毒,煎服可平喘镇咳。
外用制剂:
赤芍,行瘀、止痛、凉血、消肿。主治:治瘀滞经闭、疝瘕积聚、腹痛、胁痛、衄血、血痢、肠风下血、目赤、痈肿、跌扑损伤。赤芍能清血分实热,散瘀血留滞。该品功能与丹皮相近,故常与丹皮相须为用。但丹皮清热凉血的作用较佳,既能清血分实热,又能治阴虚发热;而赤芍只能用于血分实热,以活血散瘀见长。《本经》:主邪气腹痛,除血痹,破坚积,寒热疝瘕,止痛,利小便,益气。
威灵仙其根及茎入药具有风湿、通经络、消骨哽之功效。在现代临床实践中其新的用途不断的被发现,如治疗胆结石,跟骨骨刺、足跟痛、食管癌等。但用药中须注意的是,气血亏虚及孕妇慎服。祛风除湿,通络止痛,消痰水,散癖积。主治痛风顽痹、风湿痹痛,肢体麻木,膝冷痛,筋脉拘挛,屈伸不利,脚气,疟疾,症瘕积聚,破伤风,扁桃体炎,诸骨鲠咽。《开宝本草》:主诸风,宣通五藏,去腹内冷滞,心隔痰水久积,症瘕痃癣气块,膀胱宿脓恶水,腰膝冷疼及疗折伤。
白芷性味归经:辛,温。归肺、胃经。祛风散寒,通窍止痛,消肿排脓,燥湿止带。《日华子本草》:治目赤胬肉,及补胎漏滑落,破宿血,补新血,乳痈、发背、瘰疬、肠风、痔瘘,排脓,疮痍、疥癣,止痛生肌,去面皯疵瘢。
延胡索主治心腹腰膝诸痛;月经不调;症瘕;崩中;产后血晕;恶露不尽;跌打损伤。有镇痛、镇静、催眠作用。活血;散瘀;理气;止痛。主心腹腰膝诸痛;月经不调;症瘕;崩中;产后血晕;恶露不尽;跌打损伤。用于胸胁、脘腹疼痛,经闭痛经,产后瘀阻,跌扑肿痛。镇痛作用:延胡索粉有镇痛作用,其止痛效价约为阿片的1/100;延胡索总碱、延胡索甲素、乙素、丑素、癸素均有镇痛作用,以乙素较强.各种剂型以醇制浸膏及粉剂作用强。《开宝本草》:主破血,产后诸病,因血所为者。妇人月经不调,腹中结块,崩中淋露,产后血运,暴血冲上,因损下血,或酒摩及煮服。
荆芥味平,性温,无毒,清香气浓。荆芥为发汗,解热药,是中华常用草药之一。能镇痰、怯风、凉血。治流行感冒,头疼寒热发汗,呕吐。祛风;解表;透疹;止血。主感冒发热;头痛;目痒;咳嗽;咽喉肿痛;麻疹;痈肿;疮疥;衄血;吐血;便血;崩漏;产后血晕。用于感冒,头痛,麻疹,风疹,疮疡初起。《纲目》:散风热,清头目,利咽喉,消疮肿。治项强,目中黑花,及生疮,阴颓,吐血,衄血,下血,血痢,崩中,痔漏。
防风性味:味辛;甘;性微温。归膀胱经;肺经;脾经;肝经。祛风解表、胜湿止痛、解痉、止痒。主治:外感风寒;头痛身痛;风湿痹痛;骨节酸痛;腹痛泄泻;肠风下血;破伤风;风疹瘙痒;疮疡初起。体外抑菌试验:采用平板法进行体外抑菌实验,结果防风对金黄色葡萄球菌、乙型溶血性链球菌、肺炎双球菌及二种霉菌(产黄青霉、杂色曲霉)等有抑菌作用,而对流感杆菌、伤寒杆菌、福氏及志贺氏痢疾杆菌无抑菌作用。《本经》:主大风头眩痛,恶风,风邪,目盲无所见,风行周身,骨节疼痹,烦满。
白及苦、甘、涩,微寒。归肺、肝、胃经。补肺,止血,消肿,生肌,敛疮。治肺伤咳血,衄血,金疮出血,痈疽肿毒,溃疡疼痛,汤火灼伤,手足皲裂。《本经》:″主痈肿恶疮败疽,伤阴死肌,胃中邪气,贼风痱缓不收。″《日华子本草》:″止惊邪、血邪,痢疾,赤眼,症结,发背,瘰疬,肠风,痔瘿,刀箭疮扑损,温热疟疾,血痢,汤火疮,生肌止痛,风痹。″
土鳖虫:土鳖虫是一味中药,为鳖蠊科昆虫地鳖(Eupolyphaga sinensisWalker)或冀地鳖(Steleophaga plancyi,即Boleny)的雌虫干燥体。具有破血逐瘀、续筋接骨之功效,并且有溶栓机制。其性寒、味咸,有毒,能入心肝脾三经,具有逐瘀、破积、通络、理伤以及接骨续筋、消肿止痛、下乳通经等功效,是理血伤科要药,适用于癌瘕积聚、血滞经闭、产后瘀血腹痛、跌打损伤、木舌、重舌等病症。跌打损伤,筋伤骨折,瘀肿疼痛。本品咸寒入血,主入肝经,性善走窜,能活血消肿止痛,续筋接骨疗伤,为伤科常用药,尤多用于骨折筋伤,瘀血肿痛。可单用研末调敷,或研末黄酒冲服;临床常与自然铜、骨碎补、乳香等同用。
地龙:《本草纲目》称之为具有通经活络、活血化瘀、预防治疗心脑血管疾病作用。地龙性寒味咸。功能:清热、平肝、止喘、通洛。主治高热狂燥,惊风抽搐,风热头痛,目赤、半身不遂等。地龙提供取液有良好的定咳平喘的作用。
本发明内服蜜丸剂的制作过程为:将当归1000g,黄芪1000g,丹参1000g,桃仁1000g,红花1000g,香附1000g,白芍1000g,鸡血藤1000g,川芎1000g,熟地1000g,佛手1000g,莪术1000g,秦艽1000g,柴胡1000g,郁金1000g,旋覆花1000g,取原料加入5-10倍量的乙醇中浸泡1-2小时,加热提取2次,每次1-2小时,去上清液,合并提取液,100-120目滤过,再经截流分子量为5000-10000的超滤柱超滤,超滤液减压浓缩相对密度为80℃时1.36的浸膏,加热浓缩至膏状,静置备用,成为组分1;将乙醇提取过的药渣放入10倍量水中,加热回流提取2次,每次提取时间为1~2小时,100-120目滤过,再经截流分子量为5000-10000的超滤柱超滤,超滤液减压浓缩相对密度为80℃时1.36的浸膏,加热浓缩至膏状,静置备用,成为组分2;将合并后组分1和组分2的膏状放入减压浓缩罐内,减压浓缩至相对密度为1.20,温度至60℃-70℃的浸膏;放入烘箱,烘干后冷却,与蜂蜜混在一起搓成细条,腊封包装。
本发明胶囊剂的制作过程为:将当归1200g,黄芪1100g,丹参1200g,桃仁1200g,红花1100g,香附1200g,白芍1200g,鸡血藤1200g,川芎1100g,熟地1100g,佛手1200g,莪术1200g,秦艽1100g,柴胡1200g,郁金1200g,旋覆花1100g,加入10倍量乙醇中加热提取2次,每次1~2小时,将2次提取液合并静置;将上述乙醇提取过的组份原料药材的药渣加10倍量水加热回流提取2次,每次1~2小时,将2次提取液合并静置。将上述两种提取液合并,减压回收乙醇并浓缩至药液浓度为0.6g生药/mL,抽滤后,滤液的相对密度约为20℃时1.08;减压至0.03-0.08MPa,温度保持在60-80℃,浓缩至相对密度为1.20,温度至60℃-70℃的浸膏,放入烘箱干燥得到组份药粉,装入胶囊制为胶囊剂。可以每12粒为一版。
本发明颗粒剂的制作过程为:取当归1300g,黄芪1300g,丹参1200g,桃仁1200g,红花1200g,香附1100g,白芍1200g,鸡血藤1300g,川芎1200g,熟地1300g,佛手1300g,莪术1300g,秦艽1300g,柴胡1200g,郁金1200g,旋覆花1300g,取原料加入5-10倍量的乙醇中浸泡1-2小时,加热提取2次,每次1-2小时,去上清液,合并提取液,100-120目滤过,再经截流分子量为5000-10000的超滤柱超滤,超滤液减压浓缩相对密度为80℃时1.36的浸膏,加热浓缩至膏状,静置备用,成为组分1;上述乙醇提取过的组份原料药材的药渣加10倍量水加热回流提取2次,每次1~2小时,将2次提取液合并静置;将上述两种提取液合并,减压回收乙醇并浓缩至药液浓度为0.6g生药/mL,抽滤后,滤液的相对密度约为20℃时1.08;减压至0.03-0.08MPa,温度保持在60-80℃,浓缩至相对密度为1.20,温度至60℃-70℃的浸膏,成为组分2;将合并后组分1和组分2的膏状放入减压浓缩罐内,减压浓缩至相对密度为1.20,温度至60℃-70℃的膏状;掺入糊精,放入制粒机中,制成颗粒剂。
本发明外用膏剂的制备方法:
按照所述份数将白芷1000g、防风1000g、和白及1000g蒸馏成结晶,备用;取蒸馏后的药渣混合剩余原料鸡血藤1000g,川芎1000g,赤芍1000g,当归1000g,延胡索1000g,荆芥1000g,丹参1000g,威灵仙1000g,土鳖虫1000g,地龙1000g,加入5-10倍量的60-90%乙醇浸泡1-2小时,加热提取2次,每次1-2小时,去上清液,合并提取液,80-120目滤过,再经截流分子量为5000-10000的超滤柱超滤,超滤液减压浓缩相对密度为80℃时1.36的浸膏,加热浓缩,30分钟~45分钟,将浓缩液静置成浸膏状,药糊继续加热浓缩至浸膏状,静置备用,成为组分2;将蒸馏提取的组分1和乙醇提取的组分2混合,成膏剂,加适量凡士林成膏剂。
也可以用上述方法得到的药膏浸泡纱布,制成纱布剂,每晚或空闲包住病患处,慢慢按摩半个小时-1个小时。
本发明外用贴膏剂的制备方法:
按照所述份数将白芷1200g、防风1100g、和白及1200g用水蒸汽蒸馏成结晶,备用;取蒸馏后的药渣混合剩余原料鸡血藤1200g,川芎1300g,赤芍1300g,当归1300g,延胡索1300g,荆芥1300g,丹参1300g,威灵仙1300g,土鳖虫1300g,地龙1300g,加入5-10倍量的乙醇中浸泡1-2小时,加热提取2次,每次1-2小时,去上清液,合并提取液,100-120目滤过,再经截流分子量为5000-10000的超滤柱超滤,超滤液减压浓缩相对密度为80℃时1.36的浸膏,加热浓缩至膏状,静置备用,成为组分1;上述乙醇提取过的组份原料药材的药渣加10倍量水加热回流提取2次,每次1~2小时,将2次提取液合并静置;将上述两种提取液合并,减压回收乙醇并浓缩至药液浓度为0.6g生药/mL,抽滤后,滤液的相对密度约为20℃时1.08;减压至0.03-0.08MPa,温度保持在60-80℃,浓缩至相对密度为1.20,温度至60℃-70℃的浸膏,成为组分2;将合并后组分1和组分2的膏状放入减压浓缩罐内,掺入粉碎的结晶粉末,减压浓缩至相对密度为1.20,温度至60℃-70℃的膏状;压入无纺纱布,制成贴膏剂。
药理学毒性试验
急性毒性实验资料
1、实验方法
将豚鼠背部脊柱两侧将脱毛剂均匀涂上,使去毛范围约40平方厘米。洗净脱毛剂归笼观察24小时,每组豚鼠分别涂本发明中药制剂外用喷雾剂0.2、0.4和0.8ml,分别含生药92mg、184mg和368mg,另一组涂溶媒0.8ml每日二次,连续一周,实验结束后,将豚鼠处死,心,肝,肾及脱毛皮肤做病理检验。
2、结果
上述三组用药豚鼠躯干脱毛区,未见局部皮肤有水肿、充血、红斑、出血点及溃疡。用药组豚鼠毛发色泽、摄食、四肢活动等对照组无明显差异,病理组织学检查,给药组心、肝、肾及脱毛皮与对照字比较也无明显差异。
结果提示,本发明中药外用制剂无局部刺激作用,也未见全身毒性表现。表明本发明中药外用制剂使用安全。
长期毒性实验资料
1、实验方法
将豚鼠随机份成4组,每组15只。在豚鼠背部脊柱两侧将脱毛剂均匀涂上,使其脱毛范围约40平方厘米。洗净脱毛剂,观察24小时后每组豚鼠分别涂本发明内服中药制剂胶囊剂0.2、0.4和0.8ml,分别含生药92、184和368mg),另一组涂溶媒0.8ml每日二次,连续30天,观察豚鼠的一般情况,实验结束后处死动物进行血液学、血液生化及病理学检查。
2、结果
上述三组用药豚鼠躯干去毛区,未见局部皮肤有水肿、充血、红斑、出血点及溃疡。用药组与对照组动物毛发色泽、摄食、四肢活动等对照组无明显差异,血液生化检查,用药组与对照组均在正常范围。病理组织学检查,实验各组心、肝、肾及局部皮肤均未见明显病变。提示,本发明中药制剂长期用药对局部皮肤及全身重要脏器均未见明显的毒性作用。试验结果表明:本发明中药制剂实验安全。
累计毒性实验:
本发明中药制剂内服胶囊剂对小鼠按7.69、19.18和43.21g生药/kg连续用药15周(1.0ml/100g体重,每天2次)及停药3周后,结果表明:本发明中药制剂对大鼠的毛发、行为、大小便、体重、脏器重量、血象、肝肾功能、血糖、血脂等指标均无明显影响,脏器肉眼没有发现异样变化和组织学检查结果表明,用药15周及停药3周后,大鼠各脏器均无明显改变。说明本发明中药制剂内服胶囊剂对大鼠长期用药后毒性小,停药后也没有异样反应,应用安全。
药理学实验说明:
药理学实验:
微循环实验方法:
1.材料与方法:取50只小鼠,随机分成5组,每组10只(雌雄各半),对照组每鼠右耳涂生理盐水少许;阳性对照组每鼠右耳给予培元活血止痛膏,受试组分为本发明内服丸剂低剂量组400mg/kg/h、本发明内服丸剂中剂量组600mg/kg/h,本发明内服丸剂高剂量800mg/kg/h。15min后腹腔注射0.1%戊巴比妥钠0.1ml/10g麻醉动物,随后尾静脉注射0.1%肾上腺素0.1mL/10g,立即观察小鼠右耳微动静脉口径(μm)及0.2mm2毛细血管网点数.t检验处
理实验数据.
2结果与讨论
2.1.对微循环的影响
与对照组相比,受试组1对小鼠毛细血管开放数有明显增多(P<0.01);受试组2对微静脉口径和毛细血管开放数有显著增加(P<0.01);受试组3对小鼠微动、静脉口径及毛细血管开放数皆有增加(P<0.01);说明受试药能改善微循环,有活血化瘀作用(表1)。
表1、本发明对小鼠微动、静脉口径及毛细血管开放数的影响
临床试验:
肋间神经痛呈急性发病,可反复发作,时有发作性加剧。急诊病人因发病急,发作时疼痛剧烈,就诊时均希望能在短时间内缓解疼痛,但本病暂无理想的特效治疗。选取2008年1月~2012年1月到我院急诊科就诊的50例肋间神经痛病例,治疗组用本发明中药组合物治疗,对比组采用曲安奈德联合利多卡因,于疼痛部位局部注射治疗,现报告如下。
1资料与方法
1.1临床资料:50例患者中,分为2组,每组25人。男性33例,女性17例;年龄18-55岁,平均32岁;发病时间最短1h,最长3个月;左侧胸痛22例,右侧胸痛27例,双侧胸痛3例;初次发病34例,再次发病16例。16例再次发病者既往均有口服NSAID类药物及外用药物史,均停药1个月以上复发。所有病例发作时临床表现为胸和/或背部呈刺痛或烧灼样痛,咳嗽、喷嚏、深呼吸时疼痛加剧。查体时均发现疼痛相应皮肤区感觉过敏和/或相应肋骨边缘有压痛点,范围局限于病变肋间神经分布区,以5-9肋间多见。局部皮肤均无损伤、感染。入院后行血常规、胸片、B超、心电图检查均未发现异常,排除肝胆、心血管、胸部疾病。诊断为单纯性肋间神经痛。
1.2治疗方法:治疗组:以本发明中药组合物(具体实施例方法制备),方用:内服当归12g,黄芪13g,丹参14g,桃仁13g,红花13g,香附14g,白芍13g,鸡血藤14g,川芎13g,熟地13g,佛手12g,莪术13g,秦艽13g,柴胡13g,郁金13g,旋覆花13g。制成蜜炼丸剂,每日3次,每次2丸。
外用:鸡血藤13g,川芎13g,赤芍13g,防风14g,白及14g,白芷13g,当归12g,延胡索12g,荆芥14g,丹参13g,威灵仙14g,土鳖虫14g,地龙14g。制成膏剂,每日涂抹患处,然后轻轻按摩10分钟。
对比组:患者取坐位或卧位,卧位时疼痛部位在上。查体时用笔标记肋骨边缘固定压痛点。以压痛点为中心常规消毒皮肤。使用5ml或10ml注射器抽取注射用曲安奈德8~10mg(昆明积大制药有限公司,国药准字H53021604)+2%利多卡因注射液100mg(天津药业集团新郑股份有限公司,国药准字H41023668),在疼痛部位上沿肋骨下缘进针,超过肋骨下缘后回抽注射器无回血、回气时,缓慢注射药液,注射完毕后拔针,注射点按压3-5min。治疗效果不理想时,第2d可在疼痛部位使用同样方法重复注射,最多3次。所有病人无应用肾上腺皮质激素禁忌证。
1.3疗效判定标准通过留观部分患者、门诊随访及电话随访观察疗效。(1)治愈:疼痛于用药后消失;(2)有效:疼痛于用药后减轻,3d内消失;(3)无效:疼痛于治疗3d后仍无改善。同时观察治疗过程中患者有无出现明显不良反应。
2结果
50例患者中,治疗组治愈21例,有效3例,无效1例,总有效率96%。对比组在注射药液后5-10min内12例患者疼痛、消失,1例病人失访;5例患者0.5h内疼痛减轻,其中3例患者第2d重复注射后疼痛消失,2例患者第3d重复治疗后疼痛消失。有1例女病人于治疗后第2d出现注射部位皮下瘀斑,局部湿热敷后皮下瘀斑于第4d消退。其余病人均未出现明显不良反应。
3讨论
肋间神经痛又称肋间神经炎,实际上仅仅是一种症状的名称,分原发性和继发性两种,临床上以继发性肋间神经痛多见,原发性肋间神经痛较少见。
继发性肋间神经痛是由邻近器官和组织病变引起,如胸腔器官病变(胸膜炎、慢性肺部炎症、主动脉瘤等)、脊柱和肋骨的损伤、老年性脊椎骨性关节炎、胸椎段脊柱畸形、胸椎段脊髓肿瘤,常压迫神经根而出现症状,带状疱疹病毒引起的肋间神经炎,也可出现肋间神经痛。带状疱疹引起的肋间神经痛因局部确定固定压痛点困难,对有皮疹及局部皮肤感染者未使用该方法。对于肋间神经痛的治疗,中医使用外用药膏剂、针刺配合中药、穴位刺络拔罐、电针等治疗获得满意疗效。但从方便快捷方面看,西医可能更适合急诊病人。但不会治本。使用强的松龙注射神经干或外侧支治疗肋间神经痛,疗效确切。强的松和曲安奈德均为肾上腺皮质糖皮质激素,具有强而持久抗炎作用,能抑制感染性和非感染性炎症,减轻充血、降低毛细血管的通透性,抑制炎症细胞(淋巴细胞、粒细胞、巨噬细胞等)向炎症部位移动,阻止炎症介质如激肽类、组织胺、慢反应物质等发生反应,抑制吞噬细胞的功能,稳定溶酶体膜,阻止补体参与炎症反应,抑制炎症后组织损伤的修复。利多卡因为酰胺类局麻药,能在短时间内有效缓解疼痛。
具体实施例:李某,男,36岁,教师,双侧肋间疼痛2个月,曾到医院检查,排除肝胆实质性病变。诊断为肋间神经痛。西医用药控制住疼痛回去上班。不就复发,到本院治疗。主诉:双肋仍感到隐隐作痛,情绪紧张或劳累时增强。兼见口干舌燥,眼睛发涩,舌红苔少,脉细稍悬数。诊断肋间神经痛,属于肝气郁结型。方用:内服当归12g,黄芪12g,丹参14g,桃仁13g,红花13g,香附12g,白芍13g,鸡血藤12g,川芎13g,熟地13g,佛手12g,莪术13g,秦艽13g,柴胡13g,郁金13g,旋覆花12g。制成蜜炼丸剂,每日3次,每次2丸。
外用:鸡血藤13g,川芎12g,赤芍13g,防风14g,白及14g,白芷13g,当归12g,延胡索12g,荆芥14g,丹参13g,威灵仙14g,土鳖虫14g,地龙14g。制成膏剂,每日涂抹患处,然后轻轻按摩5分钟。用药3天后,感觉症状减轻,坚持一个月后痊愈。
Claims (10)
1.一种治疗肋间神经痛的中药组合物,其特征在于,由内服药物和外用药物组成,
所述内服药物中各种原料的重量份数包括:当归10~20份,黄芪10~20份,丹参10~20份,桃仁10~20份,红花10~20份,香附10~20份,白芍10~20份,鸡血藤10~20份,川芎10~20份,熟地10~20份,佛手10~20份,莪术10~20份,秦艽10~20份,柴胡10~20份,郁金10~20份,旋覆花10~20份;
外用药物中各种原料的重量份数包括:鸡血藤10~20份,川芎10~20份,赤芍10~20份,防风10~20份,白及10~20份,白芷10~20份,当归10~20份,延胡索10~20份,荆芥10~20份,丹参10~20份,威灵仙10~20份,土鳖虫10~20份,地龙10~20份。
2.根据权利要求1所述治疗肋间神经痛的中药组合物,其特征在于,
所述内服药物中各种原料的重量份数包括:当归10~15份,黄芪10~15份,丹参10~15份,桃仁10~15份,红花10~15份,香附10~15份,白芍10~15份,鸡血藤10~20份,川芎10~20份,熟地10~20份,佛手10~20份,莪术10~20份,秦艽10~20份,柴胡10~20份,郁金10~20份,旋覆花10~20份;
外用药物中各种原料的重量份数包括:鸡血藤10~15份,川芎10~15份,赤芍10~15份,防风10~15份,白及10~15份,白芷10~15份,当归10~20份,延胡索10~20份,荆芥10~20份,丹参10~20份,威灵仙10~20份,土鳖虫10~20份,地龙10~20份。
3.根据权利要求1所述治疗肋间神经痛的中药组合物,其特征在于,
所述内服药物中各种原料的重量份数包括:当归10~20份,黄芪10~20份,丹参10~20份,桃仁10~20份,红花10~20份,香附10~20份,白芍10~20份,鸡血藤10~15份,川芎10~15份,熟地10~15份,佛手10~15份,莪术10~15份,秦艽10~15份,柴胡10~15份,郁金10~15份,旋覆花10~15份;
外用药物中各种原料的重量份数包括:鸡血藤10~20份,川芎10~20份,赤芍10~20份,防风10~20份,白及10~20份,白芷10~20份,当归10~15份,延胡索10~15份,荆芥10~15份,丹参10~15份,威灵仙10~15份,土鳖虫10~15份,地龙10~15份。
4.一种如权利要求1~3中任一项所述治疗肋间神经痛的中药组合物的制备方法,其特征在于,所述内服制剂的剂型为胶囊剂,其制备方法包括:
a、取原料药放入乙醇中浸泡,热提取2次,成膏状,为组分1;
b、药渣加水提取2次,浓缩过滤为膏状,为组分2;
c、将上述两种膏状合并,浓缩成粉末装入胶囊。
5.根据权利要求4所述治疗肋间神经痛的胶囊剂的制备方法,其特征在于,所述步骤a中,取原料药加入5-10倍量的乙醇中浸泡1-2小时,加热提取2次,每次1-2小时,合并提取液,静置后去上清液,然后100-120目滤过,再经截流分子量为5000-10000的超滤柱超滤,超滤液减压浓缩相对密度为80℃时1.36的浸膏,静置备用,成为组分1。
6.根据权利要求4所述治疗肋间神经痛的胶囊剂的制备方法,其特征在于,所述步骤b中,上述乙醇提取过的原料药的药渣加10倍量水,加热回流提取2次,每次1~2小时,将2次提取液合并静置;将上述两种提取液合并,减压回收乙醇并浓缩至药液浓度为0.6g生药/mL,抽滤后,滤液的相对密度约为20℃时1.08;浓缩至相对密度为1.20,温度至60℃-70℃的浸膏,静置备用,成为组分2。
7.根据权利要求4所述治疗肋间神经痛的胶囊剂的制备方法,其特征在于,所述步骤c中,将组分1和组分2的浸膏合并,然后放入减压浓缩罐内,减压浓缩至相对密度为1.20,然后取出,放入烘干机烘干成粉末,放入胶囊中,成胶囊剂。
8.一种如权利要求1~3中任一项所述治疗肋间神经痛的中药组合物的制备方法,其特征在于,所述内服制剂的剂型为丸剂,制备方法包括:
将所述组份原料药去杂,晾干,粉碎成颗粒,加水浸泡1小时;将浸泡好的原料置多功能提取罐中加水煎煮二次;第一次加总药材10倍量的水,煎煮1.5~2小时,取煎液,滤过;第二次加总量7倍量的水,煎煮1~1.2小时,取两次煎液混合,滤过;将过滤的滤液置入双效真空浓缩器中,浓缩至90℃时相对密度为1.05的浓缩液,置0~5℃低温冷藏24小时;将冷藏液加0.3%的助滤剂硅藻土,过滤,滤液再置入双效真空浓缩器中,浓缩至每1ml含1g生药量,直接干燥成粉末;然后加蜂蜜搓成丸剂。
9.一种如权利要求1~3中任一项所述治疗肋间神经痛的中药组合物的制备方法,其特征在于,所述外用制剂的剂型为膏剂的制备方法包括以下步骤:
按照所述份数先将白芷、防风、和白及水蒸气法蒸馏,得到结晶物,作为组分1备用;取蒸馏后的药渣混合剩余原料加入5-10倍量的60-90%乙醇浸泡1-2小时,加热提取2次,每次1-2小时,去上清液,合并提取液,80-120目滤过,再经截流分子量为5000-10000的超滤柱超滤,超滤液减压浓缩相对密度为80℃时1.36的浸膏,加热浓缩,30分钟~45分钟,将浓缩液静置成浸膏状,药糊继续加热浓缩至浸膏状,静置备用,成为组分2;将蒸馏提取的组分1和乙醇提取的组分2混合,加凡士林成膏剂。
10.根据权利要求1~9所述治疗肋间神经痛的中药组合物,其特征在于,所述组合物的内服药物剂型为:糖衣片剂、薄膜衣片剂、肠溶衣片剂、硬胶囊剂、软胶囊剂、口服液、口含剂、颗粒剂、冲剂、丸剂、散剂、丹剂、溶液剂或注射剂;所述组合物的外用药物剂型为:喷雾剂、粉剂、散剂、软膏剂、纱布剂或贴膏剂。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310751102.2A CN103736017A (zh) | 2013-12-31 | 2013-12-31 | 一种治疗肋间神经痛的中药组合物及其制备方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310751102.2A CN103736017A (zh) | 2013-12-31 | 2013-12-31 | 一种治疗肋间神经痛的中药组合物及其制备方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103736017A true CN103736017A (zh) | 2014-04-23 |
Family
ID=50493133
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310751102.2A Pending CN103736017A (zh) | 2013-12-31 | 2013-12-31 | 一种治疗肋间神经痛的中药组合物及其制备方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103736017A (zh) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104208291A (zh) * | 2014-08-26 | 2014-12-17 | 青岛恒波仪器有限公司 | 一种治疗热淋的中药制剂及其制备方法 |
| CN104274755A (zh) * | 2014-10-30 | 2015-01-14 | 青岛恒波仪器有限公司 | 一种治疗小儿遗尿的中药制剂及其制备方法 |
| CN104547703A (zh) * | 2015-01-12 | 2015-04-29 | 杜卫兵 | 一种治疗小儿湿疹的中药组合物及其制备方法 |
| CN104623537A (zh) * | 2015-01-15 | 2015-05-20 | 汤华淑 | 一种治疗肋间神经痛的中药组合物 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101396532A (zh) * | 2008-11-06 | 2009-04-01 | 王希强 | 筋骨风湿寒痛膏 |
| CN102716312A (zh) * | 2012-06-20 | 2012-10-10 | 李承平 | 一组祛瘀通络药片 |
-
2013
- 2013-12-31 CN CN201310751102.2A patent/CN103736017A/zh active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101396532A (zh) * | 2008-11-06 | 2009-04-01 | 王希强 | 筋骨风湿寒痛膏 |
| CN102716312A (zh) * | 2012-06-20 | 2012-10-10 | 李承平 | 一组祛瘀通络药片 |
Non-Patent Citations (2)
| Title |
|---|
| 郭桂雯等: "柴胡疏肝散合桃红四物汤加减治疗带状疱疹后遗肋间神经痛28例", 《中国民间疗法》, vol. 17, no. 11, 30 November 2009 (2009-11-30) * |
| 黄国坚等: "活血通络酊联合微波外治带状疱疹神经痛240 例疗效观察", 《河北中医》 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104208291A (zh) * | 2014-08-26 | 2014-12-17 | 青岛恒波仪器有限公司 | 一种治疗热淋的中药制剂及其制备方法 |
| CN104274755A (zh) * | 2014-10-30 | 2015-01-14 | 青岛恒波仪器有限公司 | 一种治疗小儿遗尿的中药制剂及其制备方法 |
| CN104547703A (zh) * | 2015-01-12 | 2015-04-29 | 杜卫兵 | 一种治疗小儿湿疹的中药组合物及其制备方法 |
| CN104623537A (zh) * | 2015-01-15 | 2015-05-20 | 汤华淑 | 一种治疗肋间神经痛的中药组合物 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102847063B (zh) | 一种治疗气血两虚血瘀型糖尿病足的中药组合物及其制备方法 | |
| CN102078569B (zh) | 一种治疗肝癌的中药制剂及其制备方法 | |
| CN103520572A (zh) | 一种用于治疗特应性皮炎的中药组合物及其制备方法 | |
| CN103751633A (zh) | 一种治疗下肢静脉曲张的中药组合物及其制备方法 | |
| CN104666579A (zh) | 一种治疗膝关节滑膜炎的中药组合物及其制备方法 | |
| CN104666698A (zh) | 一种治疗膝关节滑膜炎的中药外用膏剂及其制备方法 | |
| CN101569739B (zh) | 一种治疗胆囊炎的中药组合物及其制备方法 | |
| CN102772712B (zh) | 一种治疗热毒炽盛血瘀型糖尿病足的中药组合物 | |
| CN103736017A (zh) | 一种治疗肋间神经痛的中药组合物及其制备方法 | |
| CN102178818B (zh) | 一种治疗乳腺癌的中药组合物及其制备方法 | |
| CN105250619A (zh) | 一种治疗内在性子宫内膜异位症的中药及其制备方法 | |
| CN105125677A (zh) | 治疗原发性三叉神经痛的制剂丸剂的制备方法 | |
| CN103751309B (zh) | 一种治疗肋间神经痛的中药外用制剂及其制备方法 | |
| CN103100017B (zh) | 一种缓解筋骨疼痛、关节疼痛的中药保健品及其制备方法 | |
| CN104873948A (zh) | 一种治疗血管穿刺引起动脉血栓的中药制剂及其制备方法 | |
| CN104225275A (zh) | 一种治疗脑血栓的中药组合物及其制备方法 | |
| CN104771678A (zh) | 一种治疗血栓性静脉炎的药物及其制备方法 | |
| CN103751708A (zh) | 一种治疗下肢静脉曲张的中药外用制剂及其制备方法 | |
| CN104383050B (zh) | 一种内外结合治疗风湿性关节炎的药物及制备方法 | |
| CN103751467A (zh) | 一种治疗腰背筋膜炎的中药组合物及其制备方法 | |
| CN104888098A (zh) | 一种用于关节置换后静脉血栓的中药制剂及制备方法 | |
| CN105456933A (zh) | 一种活血化瘀、通经活络的中药及其制备方法 | |
| CN103933359A (zh) | 用于祛除瘢痕疙瘩的药物组合物及其制备方法 | |
| CN104998208A (zh) | 一种用于会阴部瘢痕挛缩畸形的中药制剂及其制备方法 | |
| CN105362944A (zh) | 一种治疗骨科扭挫伤的中药膏剂 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20140423 |
